Background: The latest update of the BIG 1-98 study (74 months) applied IPCW to estimate treatment effect in the presence of selective crossover (25% of TAM pts). The IPCW hazard ratio for overall ...
Denosumab for Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors: Incremental Benefit, Debatable Value ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果